
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Suramin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : PaxMedica
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, PaxMedica gains certain suramin research assets to support the submission for the approval of PAX-101 (suramin sodium), specifically for the treatment of African Sleeping Sickness caused by the Trypanosoma brucei rhodesiense para...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 31, 2023
Lead Product(s) : Suramin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : PaxMedica
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Suramin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Rex Health Ventures
Deal Size : $4.5 million
Deal Type : Series B Financing
Rediscovery Life Sciences Completes $4.5M Series B Financing
Details : RLS will use the proceeds to fund a Phase 2 trial of suramin in diuretic resistant Acute Kidney Injury (AKI).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 23, 2020
Lead Product(s) : Suramin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Rex Health Ventures
Deal Size : $4.5 million
Deal Type : Series B Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Suramin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Suramin in Subjects With Furosemide-Resistant AKI
Details : Suramin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Kidney Injury.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2020
Lead Product(s) : Suramin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
